{
    "nctId": "NCT02449824",
    "briefTitle": "MRI and Early Decision-making in Chemotherapy for Breast Cancer",
    "officialTitle": "Characterising Early Response to Neoadjuvant Chemotherapy With Quantitative Breast MRI",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Change in tumour blood flow between baseline and after 1 cycle of neoadjuvant chemotherapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Newly diagnosed large but operable invasive carcinoma of the breast. All molecular subtypes are eligible and incidentally detected small volume metastatic disease is NOT an exclusion criterion.\n* Clinical indication for NAC as determined by the Breast Therapeutic MDT.\n* Sufficient biopsy material taken at diagnosis to measure the standard molecular markers.\n* Participant is willing and able to give informed consent for participation in the study.\n* Female, aged 18 years or above.\n* Histologically or cytologically confirmed invasive carcinoma of the breast and having received no prior treatment for this.\n* Female participants of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study.\n* Participant has adequate renal function (estimated glomerular filtration rate \u2265 30 ml/min).\n* In the Investigator's opinion, is able and willing to comply with all study requirements.\n\nExclusion Criteria:\n\n* Previous breast cancer treated with radiotherapy or chemotherapy or recurrent breast cancer.\n* Female participant who is pregnant, lactating or planning pregnancy during the course of the study.\n* Significant renal impairment (estimated glomerular filtration rate \\< 30 ml/min).\n* Contraindication to MRI.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}